Jeremy Nathans
Jeremy Nathans | |
|---|---|
| Born | July 31, 1958 |
| Education | MIT (B.S.), Stanford University (Ph.D.) |
| Known for | Opsin genes and colour vision, the mechanisms underlying red–green colour blindness, trichromatic mouse models, Brn3/POU4F transcription factors, Wnt receptor discovery, planar cell polarity, Norrin/Frizzled4 signaling, Retinal disease genetics, and CNS vascular biology. |
| Spouse | Thanh Huynh |
| Children | Riva (b. 1988); Rosalie (b. 1994) |
| Awards | World Laureate Association Prize in Life Science or Medicine (2024); Nemmers Prize in Medical Science (2022); Benjamin Franklin Medal in the Life Science (2020); Helen Keller Prize in Vision Research (2019); member, National Academy of Medicine (2011); Edward Scolnick Prize in Neuroscience (2009); Champalimaud Award for Vision Research (2008); member, National Academy of Sciences (1996) |
| Scientific career | |
| Fields | Molecular biology and genetics; neuroscience; ophthalmology |
| Workplaces | Johns Hopkins University |
| David Hogness | |
| Website | nathanslab |
Jeremy Nathans (born July 31, 1958) is a professor of molecular biology and genetics at Johns Hopkins University School of Medicine. From 1988 to 2026. He was investigator of the Howard Hughes Medical Institute. He is a member of the National Academy of Sciences and the National Academy of Medicine.
Nathans is known for isolating and characterising the opsin genes that encode the human short-wave (blue), medium-wave (green), and long-wave (red) color vision receptors, work that revealed the molecular genetic basis for trichromatic color vision and for inherited variation in red-green color vision. His subsequent research identified the molecular mechanisms of blue cone monochromacy and tritanopia (loss of short-wave sensitivity). The locus control region that governs mutually exclusive cone opsin expression, and the molecular mechanisms of several inherited retinal diseases, including Stargardt disease and vitelliform macular dystrophy. His laboratory also discovered the Frizzled family of Wnt receptors and the Norrin/Frizzled4 signaling pathway, which functions as an essential regulator of the blood-retina barrier. This work has led to a clinical-stage drug candidate for diabetic macular edema.
As of 2026, Nathans’ published work has been cited more than 47,000 times on Google Scholar, with an h-index of 108.